Telix Pharmaceuticals (TLPPF) Cash & Current Investments (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Cash & Current Investments for 4 consecutive years, with $292.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments changed N/A year-over-year to $292.3 million in Q2 2026; TTM through Jun 2026 was $292.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $179.0 million, down 64.29% from the prior year.
• Cash & Current Investments was $292.3 million for Q2 2026 at Telix Pharmaceuticals, up from $179.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $501.2 million in Q4 2024 and troughed at $88.2 million in Q4 2023.
• A 4-year average of $265.2 million and a median of $235.6 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 468.23% in 2024 and slumped 64.29% in 2025, its largest moves.
• Over 4 years, Cash & Current Investments stood at $88.2 million in 2023, then soared by 468.23% to $501.2 million in 2024, then tumbled by 64.29% to $179.0 million in 2025, then jumped by 63.34% to $292.3 million in 2026.
• The last three Cash & Current Investments figures came in at $292.3 million (Q2 2026), $179.0 million (Q4 2025), and $501.2 million (Q4 2024), per Business Quant data.